PL2327763T3 - Generowanie komórek T specyficznych względem antygenu - Google Patents

Generowanie komórek T specyficznych względem antygenu

Info

Publication number
PL2327763T3
PL2327763T3 PL10179257T PL10179257T PL2327763T3 PL 2327763 T3 PL2327763 T3 PL 2327763T3 PL 10179257 T PL10179257 T PL 10179257T PL 10179257 T PL10179257 T PL 10179257T PL 2327763 T3 PL2327763 T3 PL 2327763T3
Authority
PL
Poland
Prior art keywords
cells
antigen specific
generation
directed
specific
Prior art date
Application number
PL10179257T
Other languages
English (en)
Inventor
Dolores Schendel
Susanne Wilde
Thomas Blankenstein
Original Assignee
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh, Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) filed Critical Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Publication of PL2327763T3 publication Critical patent/PL2327763T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464454Enzymes
    • A61K39/464456Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL10179257T 2005-08-05 2006-08-04 Generowanie komórek T specyficznych względem antygenu PL2327763T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05017128 2005-08-05
EP06007539 2006-04-10
EP06776623A EP1910521B1 (en) 2005-08-05 2006-08-04 Generation of allorestricted antigen specific t cells
EP10179257.0A EP2327763B1 (en) 2005-08-05 2006-08-04 Generation of antigen specific T cells

Publications (1)

Publication Number Publication Date
PL2327763T3 true PL2327763T3 (pl) 2018-08-31

Family

ID=37598202

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10179257T PL2327763T3 (pl) 2005-08-05 2006-08-04 Generowanie komórek T specyficznych względem antygenu

Country Status (11)

Country Link
US (2) US8486694B2 (pl)
EP (3) EP3369812B1 (pl)
JP (3) JP5079697B2 (pl)
AT (1) ATE484578T1 (pl)
DE (1) DE602006017556D1 (pl)
DK (2) DK2327763T3 (pl)
ES (2) ES2842878T3 (pl)
HU (1) HUE038833T2 (pl)
PL (1) PL2327763T3 (pl)
PT (1) PT2327763T (pl)
WO (1) WO2007017201A1 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
EP3369812B1 (en) * 2005-08-05 2020-10-07 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Generation of antigen specific t cells
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
AU2010210083C1 (en) * 2009-02-09 2015-11-26 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific T cell receptor sequences and use thereof
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
SI2618835T1 (sl) * 2010-09-20 2017-10-30 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t celični receptorji in t celični epitopi
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
ES2689512T3 (es) * 2011-09-15 2018-11-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptores de células T que reconocen MAGE restringido por HLA-A1 o a HLA-Cw7
CN110511278A (zh) 2012-05-07 2019-11-29 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
CN110241086A (zh) * 2012-06-11 2019-09-17 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
WO2014039675A2 (en) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
WO2015075175A1 (en) 2013-11-22 2015-05-28 Cellectis Method for generating batches of allogeneic t-cells with averaged potency
JP2017511375A (ja) * 2014-03-20 2017-04-20 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 養子細胞療法のための腫瘍浸潤リンパ球
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
AU2014407540C1 (en) * 2014-10-02 2021-07-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
JP2017535284A (ja) * 2014-11-05 2017-11-30 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
SG11201707540QA (en) * 2015-03-16 2017-10-30 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
NZ737400A (en) 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
CA2993431A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Nuclease based knockouts of immunological checkpoint genes in immune cells
AU2016323017B2 (en) * 2015-09-15 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
KR20200100858A (ko) 2015-12-23 2020-08-26 메디진 이뮤노테라피스 게엠바하 수지상 세포 조성물
EP3397263B1 (en) * 2015-12-30 2023-09-20 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
MX2019003176A (es) * 2016-09-23 2019-07-04 Hutchinson Fred Cancer Res Receptores de linfocitos t (tcr) especificos del antigeno menor de histocompatibilidad (h) ah-1 y sus usos.
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
TWI822726B (zh) 2018-02-26 2023-11-21 德商梅迪基因免疫治療公司 Nyeso t細胞受體
JP2022500034A (ja) * 2018-09-10 2022-01-04 トルク セラピューティクス, インコーポレイテッド 抗原特異的tリンパ球ならびに抗原特異的tリンパ球を作製および使用する方法
US20230041057A1 (en) * 2018-09-27 2023-02-09 Genocea Biosciences, Inc. Treatment methods
JP2022511974A (ja) * 2018-12-12 2022-02-01 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫抑制のための組成物および方法
TW202102530A (zh) 2019-04-04 2021-01-16 德商梅迪基因免疫治療公司 黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
JP7340144B2 (ja) * 2019-10-02 2023-09-07 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するt細胞を単離する方法
JP6878544B2 (ja) * 2019-10-02 2021-05-26 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するt細胞を単離する方法
EP4126962A1 (en) 2020-04-01 2023-02-08 Medigene Immunotherapies GmbH Cd3-fusion protein and uses thereof
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するt細胞受容体を単離する方法
US20230287345A1 (en) 2020-08-18 2023-09-14 Medigene Immunotherapies Gmbh ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY
IL301543A (en) 2020-09-24 2023-05-01 Medigene Immunotherapies Gmbh PRAME-specific T-cell receptors and uses thereof
WO2023175069A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library for pramevld tcrs
WO2023175070A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
DE50207025D1 (de) * 2002-08-23 2006-07-06 Deutsches Rheuma Forschungszen Verfahren zum Nachweis und zur Isolierung von T-Lymphozyten, die ein definiertes Antigen erkennen
EP3369812B1 (en) * 2005-08-05 2020-10-07 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Generation of antigen specific t cells

Also Published As

Publication number Publication date
US20100189728A1 (en) 2010-07-29
WO2007017201A1 (en) 2007-02-15
PT2327763T (pt) 2018-05-11
EP1910521A1 (en) 2008-04-16
JP2009502185A (ja) 2009-01-29
ES2842878T3 (es) 2021-07-15
JP2016135127A (ja) 2016-07-28
ATE484578T1 (de) 2010-10-15
EP3369812B1 (en) 2020-10-07
EP1910521B1 (en) 2010-10-13
US8486694B2 (en) 2013-07-16
EP3369812A1 (en) 2018-09-05
JP5079697B2 (ja) 2012-11-21
ES2672895T3 (es) 2018-06-18
JP2012213402A (ja) 2012-11-08
DK2327763T3 (en) 2018-05-22
DK1910521T3 (da) 2011-02-07
US20140141026A1 (en) 2014-05-22
DE602006017556D1 (de) 2010-11-25
HUE038833T2 (hu) 2018-11-28
EP2327763B1 (en) 2018-03-14
EP2327763A1 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
HUE038833T2 (hu) Antigénspecifikus T-sejtek létrehozása
Wolf et al. Novel approaches to exploiting invariant NKT cells in cancer immunotherapy
Jenq et al. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer
Mandal et al. Polymer-based synthetic dendritic cells for tailoring robust and multifunctional T cell responses
DK1639013T3 (da) Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
EA201100663A1 (ru) Соединения, которые увеличивают количество гематопоэтических стволовых клеток
WO2003046141A3 (en) Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
WO2005004592A8 (en) Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2004003142A3 (en) Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
BR0211491A (pt) Geração de células dendrìticas totalmente madura e estáveis de produtos de leucafereses para aplicações clìnicas
ATE544849T1 (de) Aktivierte dendritische zellen, therapieverfahren unter verwendung der dendritischen zellen sowie verfahren zur kultivierung von gamma-delta-t- zellen
ATE324030T1 (de) Brassica-transformation durch teilchenbeschuss
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
NO20054238D0 (no) Inhibitorer av antigenpresentasjon ved MHC klasse II-molekyler og fremgangsmate for anvendelse av disse
GB2379446A (en) Cells,culture methods and their uses
Lawrence Human iPS cells for clinical applications and cellular products
Lee et al. Gene editing using CRISPR enables FOXP3 gene repair in HSPCs and IPEX patient T cells
WO2006101891A3 (en) Antigens targeted by pathogenic t cells in type 1 diabetes and uses thereof
Jiang et al. Adoptive cell therapy using in vitro generated human CD4+ CD25+ regulatory t cells with indirect allospecificity to promote donor-specific transplantation tolerance
Knueppel et al. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model
Karimi et al. Immunoregulatory Properties of Human Bone Marrow Mesenchymal Stem Cells on T Lymphocyte Proliferation.